2seventy narrows focus and lays off 40% of its workforce
US-based 2seventy bio, which is working with Novo Nordisk on a hemophilia drug, will lay off 176 employees and focus on growth of approved cancer drug.
A major round of layoffs is being initiated at US gene company 2Seventy Bio, with whom Novo Nordisk works.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg)
